Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2309 • ACR Convergence 2023
Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus
Luis Vega Sevilla¹, Oscar E. Alvarez-González², Janett Riega-Torres³, Cassandra Michele Skinner-Taylor³, Diana Carolina Rubio Torres⁴, Lucio Vera Cabrera⁵, Dionicio A. Galarza-Delgado⁶, Jesus Alberto Cardenas-De la Garza⁷, Rodrigo J. Castillo-de la Garza⁵, Mario Alberto Aguilera Valenciano⁵, wendy Escalante⁵ and Hector Guerra⁸, ¹Hospital Universitario UANL, Garcia, Mexico, ²Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Faculty of Medicine and University Hospital Dr. José Eleuterio González, UANL, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Mexico, ⁷Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁸Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with epithelial defects and disrupted intestinal barrier, risking bacterial translocation, and promoting systemic inflammation, known as dysbiosis, which…
Abstract Number: 2325 • ACR Convergence 2023
Longitudinal ANA Titers in SLE and ANA-associated Rheumatic Diseases
Emily Littlejohn¹, Lingxuan Kong², Lu Wang² and Emily Somers², ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Antinuclear antibodies (ANAs) are a hallmark of systemic lupus erythematosus (SLE) and also a marker of subclinical autoimmunity. While a seminal study using the…
Abstract Number: 2344 • ACR Convergence 2023
Telitacicept versus Belimumab for Patients with Active Systemic Lupus Erythematosus: A Retrospective, Multicenter, Real-world Observational Study
Zhu Chen¹, Huizhi Jin¹, Yujing Li¹, Guosheng Wang¹, Xiaomei Li², Zhijun Li³, Lin Niu⁴ and Haifeng Pan⁵, ¹University of Science and Technology of China, Hefei, China, ²University of Science and Technology of China, Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei, China, ³Bengbu Medical University, Bengbu, China, ⁴Fuyang People's Hospital, Fuyang, China, ⁵Anhui Medical University, Hefei, China
Background/Purpose: The past decade has witnessed the innovation of several biologics in the treatment of systemic lupus erythematosus (SLE), most of which target B cells,…
Abstract Number: 2458 • ACR Convergence 2023
The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center
Emily Beil¹, Eyal Muscal², Abiodun Oluyomi³, Omar Rosales³, Danielle Guffey⁴, Marietta DeGuzman¹, Cagri Yildirim-Toruner⁵, Andrea Ramirez³ and Erin Peckham-Gregory³, ¹Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ²Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Houston, TX, ⁴Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, ⁵Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The prevalence of childhood-onset SLE (cSLE) differs by racial/ethnic group. Yet, the role of social determinants of health (SDoH) in disease severity is not…
Abstract Number: 2551 • ACR Convergence 2023
Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis
Ioannis Parodis¹, Julius Lindblom¹, Roger A. Levy², Margherita Zen³, Nursen Cetrez¹, Alvaro Gomez⁴, Shereen Oon⁵, Christine Henning⁶, Munther Khamashta⁷, Holly A. Quasny⁸, Deven Chauhan⁹, Anca Askanase¹⁰, Ronald van Vollenhoven¹¹ and Mandana Nikpour¹², ¹Karolinska Institutet, Stockholm, Sweden, ²GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ³University of Padua, Division of Rheumatology, Department of Medicine, Padua, Italy, ⁴Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁵University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ⁶GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁷GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, ⁸GlaxoSmithKline, Research & Development, Durham, NC, ⁹GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ¹⁰Columbia University Medical Center, New York, NY, ¹¹Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, ¹²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: A key treatment goal in SLE management is the attainment of remission or LDA,1 for which various definitions exist, including “Definitions of Remission in…
Abstract Number: 0080 • ACR Convergence 2023
Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses
Neha Bhagwat¹, Kumar Penmetsa², Matt Devalaraja³, Suzana Marusic⁴, Cornelia M. Weyand⁵, Shozo Ohtsuki⁶, Peggy Scherle¹ and Kris Vaddi¹, ¹Prelude Therapeutics, Inc, Wilmington, DE, ²Thermo Fisher Scientific, Philadelphia, PA, ³Nipuna Therapeutics, Waltham, MA, ⁴Hooke Laboratories LLC, Lawrence, MA, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁶Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN
Background/Purpose: Protein arginine methyltransferase 5 (PRMT5) is the major type II PRMT that catalyzes the formation of symmetrical dimethyl arginine (SDMA) on protein substrates and…
Abstract Number: 0181 • ACR Convergence 2023
Increased Prevalence of and Acute Hospital Events Among Medicare Systemic Lupus Erythematosus Patients Living in Socially Vulnerable Counties in the United States
Emily Cosentino, John Pearce and Jim Oates, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is more prevalent and has greater adverse health outcomes in women, minorities, and individuals with low socioeconomic status (SES), particularly…
Abstract Number: 0334 • ACR Convergence 2023
Association of a Self-Report Screening Tool for Sarcopenia (SARC-F) with Functional Status Outcomes in Systemic Lupus Erythematosus
Sarah Lieber¹, Yvonne Shea², Deanna Jannat-Khah², John Carrino², M. Carrington Reid³ and Lisa Mandl¹, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Weill Cornell Medicine, New York, NY
Background/Purpose: Sarcopenia, i.e., loss of skeletal muscle mass and strength, has been associated with multiple adverse health outcomes, including mortality. Although limited data suggest that…
Abstract Number: 0552 • ACR Convergence 2023
The Impact of Antiphospholipid Antibodies on Future Atherosclerotic Cardiovascular Disease Risk in Systemic Lupus Erythematosus
YuFang Ding¹, Can Huang², Jiuliang zhao³, Qian Wang¹, Xinping Tian³, Mengtao Li³ and xiaofeng Zeng¹, ¹Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking Unoin Medical College Hospital, Beijing, China, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases (23·3 events per 1000 patient-years). Antiphospholipid antibodies (aPLs), including anticardiolipin…
Abstract Number: 0569 • ACR Convergence 2023
Serum S100A8 and S100A9 Are Useful Biomarker Indicated IFN Associated Organ Involvements in Systemic Lupus Erythematosus
Risa Wakiya¹, Hiromi Shimada¹, Shusaku Nakashima¹, Taichi Miyagi², Yusuke Ushio³, Koichi Sugihara⁴, Mao Mizusaki¹, Rina Mino⁵, Kanako Chujo⁶, Ryoko Kagawa³, Hayamasa Yamaguchi³, Tomohiro Kameda¹ and Hiroaki Dobashi¹, ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁴Kagawa University, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁶Kagawa University, Miki, Kita District, Kagawa, Japan
Background/Purpose: S100, a damage-related molecular pattern factor, was reported to be a biomarker associated with disease activity in SLE. Additional hydroxychloroquine, which could regulate IFN…
Abstract Number: 0587 • ACR Convergence 2023
Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data
Daniel Moldaver¹, Seth Anderson², Marguerite Bracher³, Roger A. Levy⁴, Holly A. Quasny⁵, Robert Wood⁶, Rosie Wild⁶, Alexandra Cusmano⁶ and Elke Rottier⁶, ¹GlaxoSmithKline, Value Evidence and Outcomes, Ontario, Canada, ²GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA, ³GlaxoSmithKline, Value Evidence and Outcomes, Stevenage, United Kingdom, ⁴GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁵GlaxoSmithKline, Research & Development, Durham, NC, ⁶Adelphi Real World, Real-World Evidence, Cheshire, United Kingdom
Background/Purpose: The clinical effectiveness of 6-month IV BEL use in SLE has previously been described in a post hoc pooled analysis from six OBSErve cohort…
Abstract Number: 0606 • ACR Convergence 2023
Risk of Damage Progression with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus
April Jorge¹, Baijun Zhou¹, Yuqing Zhang² and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Belimumab was approved for the treatment of non-renal SLE in 2011 and has been previously associated with a lower risk of damage progression when…
Abstract Number: 0827 • ACR Convergence 2023
Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease
Caleb Bolden¹, Claire Cook¹, Lucy Finkelstein-Fox¹, Xiaoqing Fu¹, Flavia Castelino¹, Hyon K. Choi², Cory Perugino¹, John Stone³, Elyse Park¹, Zachary Wallace⁴ and Daniel Hall¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with systemic autoimmune rheumatic disease (SARD) are often tasked with monitoring ambiguous and unpredictable physical symptoms on their own. Higher levels of uncertainty…
Abstract Number: 0900 • ACR Convergence 2023
Complement Deposition on Extracellular Mitochondria Induces Platelet Activation in Vitro
Marina Barguil Macedo and Christian Lood, University of Washington, Seattle, WA
Background/Purpose: Mitochondria are extruded upon cell death and platelet activation, being elevated in several inflammatory conditions, including systemic lupus erythematosus (SLE). Mitochondria are immunogenic, with…
Abstract Number: 0917 • ACR Convergence 2023
Role of Immunoglobulin Polygenic Risk in Systemic Lupus Erythematosus
Victor Gothefors-Holm¹, Sarah Reid¹, Ahmed Sayadi¹, Maija-Leena Eloranta¹, Martina Frodlund², Karoline Lerang³, Andreas Jonsen⁴, Solbritt Rantapää-Dahlqvist⁵, Anders Bengtsson⁴, Anna Rudin⁶, Oyvind Molberg³, Christopher Sjöwall², Johanna Sandling¹, Lars Rönnblom¹ and Dag Leonard¹, ¹Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ⁵Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease partly characterized by production of autoantibodies, causing inflammation and tissue damage. In this study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].